CTLA4 and neoplasm: Since the anti-tumor efficacy of the dual combination therapy (G47Δ-IL12+axitinib) was T cell dependent, it is hypothesized that ICI (i.e., anti-PD-1 or anti-CTLA4) will improve the therapeutic outcome of G47Δ-IL12+axitinib dual combination.